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Abstract
This paper explores the development of anti-epileptic drugs, starting with the earliest forms of treatment,
moving to the drugs currently in use and those recently approved by the FDA, and ending with the drugs
(and devices!) that will likely be approved for use in the near future. It covers all aspects relating to such
drugs, examining why the need for an eective drug is so signicant, how a specic medication is chosen by
a physician and his patient, the special considerations for anti-epileptic drug use in certain populations, the
1problems with the current approval process for anti-epileptic drugs by the FDA, and the scientic advances
that have been and continue to be made in the search for a safe and eective anti-epileptic drug.
Prologue: My Experience with Anti-epileptic Drugs
2.5 million people in the United States suer from epilepsy.1 I am one of them.
I was diagnosed in January 2001, the middle of my rst year of law school. I was preparing for my return to
Cambridge following Christmas vacation when, without warning or precedent, I was struck by a generalized
tonic-clonic seizure (popularly known as a grand mal seizure). In the emergency room I was prescribed the
rst of the several anti-epileptic drugs I would try. It was what I now know to be a standard \rst-line"
drug called Dilantin.
I went to a neurologist the following day, and over the next week took a series of diagnostic tests. Having
hoped that this was just a random, isolated experience (many people have a seizure at some point in their
lives, never to have one again), my parents and I were shocked and dismayed by my diagnosis: epilepsy.
Since that day, I have done my best to learn everything possible about epilepsy, both the condition in general
and mine in particular. I have learned about the causes of epilepsy (like 70 percent of other suerers, the
cause of my seizures is unknown, or idiopathic), the typical age of onset (childhood or old age { neither of
which describe me) and, through trial and error, the medications available to treat epilepsy.
1Natalie Frazin, White House-Initiated Conference on Epilepsy Emphasizes \no seizures, no side-eects" NINDS publica-
tions, at www.ninds.nih,gov. The NINDS (National Institute of Neurological Disorders and Stroke) is the primary Federal
supporter of research on disorders of the brain and nervous system.
2Finding the correct anti-seizure medication is a dicult task, and takes into account many factors. In the
patient's mind only two really matter: seizure control and side eects. My rst medication, Dilantin, did an
excellent job of controlling my seizures. Unfortunately it also had severe cognitive and psychological eects.
I was unable to concentrate on my schoolwork, unable to put thoughts together in response to questions
and, when a thought would come to me, unable to put it into words. I also found myself having tremendous
mood swings and, though I have always had a very happy, optimistic and upbeat personality, I often felt
depressed (though that could have been the diagnosis itself, the lifestyle changes that accompanied it, or
simply the eect of my rst winter in Boston). I even considered leaving Harvard Law School. Though my
family and friends were consoling and my doctors told me that these side eects were normal, I had no idea
how common they were or that other medications were available.
Complaints about my cognitive impairment nally led my doctor to change my medication, again to an
older, well-established medicine called Depakote. Besides the patient insert, I was given no notice of the
extreme side eects of this drug, and was not told of them until ve months later when, after gaining 25
pounds, continuing to feel depressed, and having three more seizures, my doctor suggested that perhaps this
was not the correct medication for me.
The next (and hopefully nal) attempt at an eective, side eect-free medication was a new and promising
drug called Lamictal. Though its long-term eects are not as well documented, clinical trials have demon-
strated its ecacy in seizure control and its relative lack of side eects. Because of the possibility of a severe
life-threatening rash or increased seizure frequency, it is necessary to start doses of Lamictal at a low level,
slowly working up while weaning the patient o the former drug.
Fortunately, despite some recent setbacks associated with my nal (and long awaited) removal from Depakote
and increase in Lamictal dosage, we seem to have found the correct drug for me (though recent tests have
not yet conrmed that nding and I may be switching again in the near future). Although we will not know
3for two years whether it is truly eective (the length of time a person has to be seizure-free before a drug is
generally concluded to be working), I feel condent that it will be, and that I will be one of the 80 percent
of epilepsy patients who are able to achieve long-term relief from their seizures through modern medical
treatments.2
I chose to write my paper on the topic of anti-epilepsy drugs for two reasons. One, obviously, is my personal
interest in the subject stemming from my own epilepsy. The other is a desire to teach others who, though
well educated, know very little about this extremely common but often misunderstood problem, its causes,
and the methods available to treat it. I was certainly one of those people a year and a half ago. Perhaps
through the posting of this paper on the class website I will shine some light on the subject for someone who
has never known somebody with epilepsy and has many misunderstandings about the disorder, someone who
knows somebody with epilepsy and would like to increase his or her knowledge of the condition, or someone
like me, who has epilepsy and derives a good deal of comfort from knowing that treatments and medications
to eradicate the seizures are constantly being developed and improved.
This paper took me a good deal of time to write, much longer than anticipated. I am sorry if it is over-
inclusive, but so much about epilepsy medication is tied to other aspects of the disorder that it was dicult
to disentangle them. Each piece of information I found led me to other interesting facts. Reading about
modern medications and their development, for example, led to books about the history of documented
epilepsy and some of the older (horric!) treatments used. Learning about the medications currently pre-
scribed led me to question why a doctor might prescribe a certain one; because that decision is due partly
to the type of seizure a person experiences, I began to research the causes for dierent types of seizures;
and because certain causes of seizures are related to a person's age, sex, or other unrelated illnesses, I wrote
about special considerations in medicating women, the old and young, and those with heart, liver, blood, or
2Seizures and Epilepsy: Hope Through Research (NINDS Publications) at http://www.ninds.nih.com.
4other diseases. It all seemed so relevant to my life that I had a dicult time sifting out what was relevant
to my paper.
In March of 2000, the White House convened a conference on the current state of epilepsy research and hopes
for the future. The slogan adopted at the conference, which was attended by scientists, doctors, people with
epilepsy, policy makers and volunteers, was to develop an epilepsy treatment with \no seizures, no side
eects."3 With adequate time, money and energy put into achieving that goal, the day is not too far o
when people with epilepsy will be able to lead normal lives, free from frightening and dangerous seizures and
free from frustrating and embarrassing side eects. A \miracle drug" is out there somewhere, just waiting
to be discovered. Like all other epilepsy suerers, I eagerly await that discovery.
The History of Anti-epileptic Drugs
\There is scarcely a substance in the world capable of passing through the gullet of a man that has not at
one time or another enjoyed the reputation of being anti-epileptic"4
| Edward H. Sieveking (1816 { 1904)
Epilepsy is an aiction as old as time. Prehistoric man most likely suered from the condition; evidence of
trephining (drilling holes in the skull to cure neurological disorders) has been found among fossilized bones.5
3See Natalie Frazin, supra note 1.
4D.F. Scott, The History of Epileptic Therapy 37 (The Parthenon Publishing Group 1993).
5Owsei Temkin, The Falling Sickness: A History of Epilepsy from the Greeks to Modern Neurology 3 (The Johns Hopkins
University Press 1994)(1945).
5Ancient Babylonian texts refer to seizure disorders, as do the texts of ancient Egypt, Greece, Rome, China
and India.6 The Bible, too, contains description of maladies that could only be categorized under the modern
denition of epilepsy.7 And, as with most diseases, along with the earliest descriptions of the disorder of
epilepsy come the earliest recorded attempts at a cure.
The seizure prevention techniques used by the ancients may seem absurd, disgusting or profoundly disturbing
today, but they represent an eort to combat what were seen at the time to be the causes of epilepsy. In
ancient Greece, for example, where emotional disturbances, \auras", and external factors such as temperature
and humidity were viewed as causal, suggested remedies included a modication of one's diet, an increase in
exercise, rest and relaxation, or a change in location so as to avoid the external causes.8 While these remedies
seem reasonable (indeed, doctors today prescribe dietary changes, the calming of emotional disturbances,
and increased rest to reduce the frequency of epileptic occurrences), other Greek remedies, from 500 B.C.
until 200 B.C., included the consumption of blood, the genitals of a seal , hippopotamus, and hare, and feces
of the crocodile.9 Clearly reason did not always rule.
The Babylonian texts, which contain the earliest recorded accounts of epilepsy, also reect a belief that a
cause of epilepsy was possession of the aicted by spirits, demons or ghosts.10 The primary cure resembled
an exorcism.11 Those who lived in India saw epilepsy as resulting from a disturbance of the mind. The
cure? Cleanliness.12 The ancient Chinese views represent their philosophy; to them, epilepsy resulted from
6Scott, supra note 4, at 13, 21, 25, 26. For references by the Babylonians and Assyrians, see M. Stol, Epilepsy in Babylonia
3 (STYX Publications 1993).
7Temkin, supra note 5, at 91. See also Scott, supra note 4, at 26-27.
8Scott, supra note 4, at 18 { 21.
9Temkin, supra note 5, at 12, 22.
10Scott, supra note 4, 21-22.
11See Stol, supra note 6, at.3.
12Scott, supra note 4, 25.
6a disturbance of the ying and the yang within the aicted person's body, best treated with herbs and
acupuncture.13 The biblical view seems to equate epileptic seizures with lunacy, and notes the dangerous
side eects associated with their occurrence.14 Unlike in most of the other cultures, many Romans did not
see epilepsy as a disturbance of the mind, but as a disturbance of the body. Epileptics were viewed as
unclean and were usually shunned and expelled from society for fear of contagion.15 Supposed remedies
for the disorder were the blood or liver of a slain gladiator.16 In extreme cases amputation was seen as
the only available cure.17 Later, in medieval times, astronomical phenomena or an imbalance in the bodily
humors were believed to contribute to epilepsy; strange treatments included exorcisms, powdered human
skull, vulture liver, and mistletoe.18 In the mid-nineteenth century, excessive masturbation was thought to
cause epilepsy and a host of other neurological disorders.19 Again, the purported \treatment" reected the
supposed cause; in cases of incurable masturbation, castration or circumcision was suggested.20
Fortunately for those who have epilepsy today, it has been a long time seizure disorders were treated with
blood or exorcisms. Especially in the past sixty years (the Modern Era of epilepsy research), society has
witnessed the development of many drugs that can control, or at least lessen the occurrence of, seizures
in most people with a minimum of undesirable side eects. Unfortunately, people with epilepsy still face
prejudice, biases, superstitions and prohibitions that can devalue their quality of life. India, for example,
continues to maintain prohibitions against driving and marriage for those with epilepsy, preventing them
13Id. at 25 { 26.
14Id. at 27. See also Temkin, supra note 5, at 91.
15Temkin, supra note 5, at.8.
16Id. at 23.
17Scott, supra note 4, 30.
18Id. at 31.
19Id. at 38.
20Temkin, supra note 5, at 231-232. See also Scott, supra note 4, 38.
7from having a normal lifestyle.21 Here in America, people with epilepsy are often discriminated against in
employment and educational pursuits, restricted from many recreational activities, and avoided by many
misinformed people due to their uncontrolled seizures or the side eects of the drugs used in attempts to
control them. To improve the quality of life of the 2.5 million Americans (and 50 million people worldwide22)
who have epilepsy, researchers and clinicians must put great eort into nding drugs that can render these
people seizure-free with few or no side eects.
In this paper I will attempt to explore the transitions that have brought us from the days of castration and
mistletoe to modern medicines, including well-known drugs such as phenytoin and carbamazepine, as well as
newcomers like lamotrigine and oxcarbazepine. I will also examine how far we still need to go in the search
for the perfect anti-epileptic drug. I will begin by explaining why an eective anti-epileptic is so essential in
improving the lives of epilepsy suerers, then will look at how a patient and his or her doctor choose from
one of the currently available medications. I will do a short survey of the drugs currently on the market,
listing their uses, side eects, and interactions with other prescription and nonprescription drugs. Special
areas of consideration, such as drugs for pregnant women, children and the elderly, or those suering from
other ailments are also within the purview of this paper. As the preceding paragraphs have pointed out,
we have come a long way in the treatment of epilepsy but there is still farther to go. \No seizures, no side
eects" is not a reality yet.
21Jim Troxell, The Americans with Disabilities Act and its Protections Against Employment Discrimination., in
Epilepsy and Law 207, 209 (Dr. Roy G. Beran, ed., 1998).
22CPR Worldwide, IEC: Anti-epilepsy Drug Lamictal (lamotrigine) Has Few Cognitive Side Eects (May 14, 2001),
available at www.docguide.com (Doctor's Guide Website).
8Why an Eective Anti-epileptic Drug is Essential
Epilepsy is a dangerous disorder with far-reaching eects on the lives of those aicted. Uncontrolled epilep-
tic seizures can be detrimental to a person's physical, mental, and emotional health, social interactions,
educational and vocational opportunities and quality of life. A recent estimate of the annual nancial cost
of epilepsy in the United States came to $4 billion23, but to the individual epileptic the tolls taken on the
body, mind, and psyche can seem much more important. Until a cure for epilepsy is discovered, medical
treatment remains the only reliable means of relieving the eects of the disorder and averting the dangers and
negative repercussions of uncontrolled seizures. An adult's ability to cope with his or her epilepsy in social
and everyday life is closely related to the degree of control exercised over his or her seizures.24 Medication is
the option chosen by most epilepsy suerers for seizure control. To enable them to lead active, normal lives,
an eective anticonvulsant drug is essential.
Physical Dangers
The loss of consciousness that accompanies some seizures causes obvious immediate physical harms, such
as falling, hitting one's head or sustaining a concussion, and biting one's tongue due to convulsions, all of
which are good reasons to avoid seizures through eective treatment. The dangers of uncontrolled seizures,
however, go far beyond the inconvenience of occasional bumps and bruises. In one study, people with
23Steven C. Schacter, MD, Epilepsy, Neurologic Treatment Vol. 19, No.1 (February 2001) 57, 57. The article was written for
the Oce of Clinical Trials and Research, and Department of Neurology, Beth Israel Deaconess Medical Center; and Department
of Neurology, Harvard Medical School. He cites a 1996 survey by Murray et. al for that gure.
24Richard Lechtenberg, MD, Epilepsy and the Family: A New Guide 38 (Harvard University Press 1999).
9epilepsy reported a higher number of illnesses in general than those without the disorder.25 Further, it
has been noted that people whose severe seizures are treatment resistant have, on average, a shorter life
expectancy than people in the general population.26 The risk of deaths among people with epilepsy to those
without is 2.3 to 1, meaning that a person with epilepsy is more than twice as likely to die at any given age
than an identical person without epilepsy.27 The minor temporary injuries cannot be written o as mere
inconveniences, but as potentially cumulative events that can lead to later problems and early mortality.
The risk of a life-threatening condition called status epilepticus, in which a seizing person does not regain
consciousness between a series of seizures or experiences seizures longer than several minutes in duration,
is greatly increased in people with uncontrolled epilepsy.28 Sudden unexplained deaths also occur twice as
frequently in those with epilepsy than among the general population, with medication by more than one
anti-epileptic drug possibly being a contributing factor.29 The common perception that the only health risks
associated with epilepsy are the minor ones due to falling during a convulsion is far from accurate. An
eective treatment is necessary to combat both the major and minor hazards of seizures.
Mental, Emotional and Psychological Eects
Physical dangers are not the only harmful eects of epilepsy that demand immediate treatment. The disorder
is also known to contribute to many mental, psychological, emotional, and social problems in those it aects.
Prejudices and biases against people with epilepsy, usually perpetuated by misunderstandings, fear, and
25See Cesare M. Cornaggia and Ettore Beghi, A Multicenter Case-reference Study on Everyday Life Risks is Epilepsy in Europe
in Epilepsy and Law, 129, 140 supra note 21.
26Id. at 141.
27Lechtenberg, supra note 24, at 55.
28Seizures and Epilepsy: Hope Through Research, supra note 2.
29Id.
10a lack of awareness of the medical (rather than psychological) nature of the disorder, can cause low self-
esteem, depression and suicide.30 Cruel treatment or avoidance by others can lead to discomfort in and
resistance to social settings and a constant fear of social interactions and pressures.31 Children are especially
at risk for psychological injury due to the disorder because of their vulnerability to the cruelty of others and
their inability to defend themselves from prejudice based on their condition. Teasing or tormenting by other
students, the trauma or fear of having a seizure in the classroom, or the frustration and embarrassment caused
by classroom manifestations of the cognitive side eects of many anti-seizure drugs (inhibiting concentration
and learning) can lead to behavioral and emotional problems.32 The perpetual fear of having a seizure,
especially in public or while in a dangerous setting, is dicult to handle even for adults. Eective anti-
seizure medications would do much to allay that fear.
Impairment of Educational and Vocational Activities
The physical, psychological and emotional problems caused by epilepsy often lead to educational and voca-
tional problems for those with the disorder. Though epilepsy is dened as a disability under the Americans
with Disabilities Act, making denial of employment or access to any educational, recreational or other ac-
tivity illegal, the eects of epilepsy and the medications currently available for its treatment, as well as
the lifestyle changes that accompany the disorder, often make that legal protection less valuable. As noted
above, the side eects of many epilepsy medications include drowsiness, diculty concentrating and other
cognitive problems, and behavioral issues in children. Frequent seizures also impair memory and contribute
to poor academic performance.33 Problems associated with a child's epilepsy can cause unwelcome absences
from school.34 Though an equal education may be technically available to children with epilepsy, in reality it
30Id.
31Id.
32Id.
33The EpiCentre website at http://137.172.248.46/treatmen.htm.
34See Cornaggia and Beghi, supra note 25, at 140.
11is dicult for them to keep up in their classes and maintain good grades. Though a patient, understanding
and helpful teacher can do much to alleviate these problems, bullying and berating by other students who
see the child with epilepsy as dumb or slow, or treat him or her as a pariah due to the seizures, can make the
educational process very dicult and uncomfortable for an epileptic child. It is not surprising that people
with epilepsy do not tend to go far in their schooling; in fact, one survey showed that only 56 percent of
people with epilepsy nish high school and about 15 percent nish college.35
The lack of higher education due to epilepsy also aects a person's job opportunities, as do the typical biases
and misunderstandings about epilepsy and the fact that many people with the disorder are unable to drive,
making it dicult to get to and from work.36 As with students in school, adults with epilepsy reported
higher numbers of absences from work in one study, making it dicult to attain and maintain steady em-
ployment.37 In fact, one out of every ve adults with epilepsy sees their greatest challenge resulting from
their disorder to be holding a job.38 Employer concerns about safety problems due to seizures, absenteeism
from work, customer and co-worker reactions when a seizure takes place, and functional limitations on the
ability of a person with epilepsy to perform a job lead to employment discrimination against those with the
disorder.39 About 25 percent of working-age people with epilepsy are unemployed.40
Epilepsy's Eects on the Patient's Lifestyle
Driving and other aspects of one's lifestyle are also challenged by an epilepsy diagnosis, but can be brought
nearly to normal with ongoing eective treatment. In most states a person with epilepsy is not allowed to
35Seizures and Epilepsy: Hope Through Research, supra note 2.
36Id.
37See Cornaggia and Beghi, supra note 25, at 140.
38Lechtenberg, supra note 24, at 43.
39Troxell, supra note 21, at 210.
40Seizures and Epilepsy: Hope Through Research, supra note 2.
12hold a driver's license until it can be proven that he or she has been seizure-free for a specied length of
time.41 Though some states have exceptions for people whose seizures follow a specic pattern (i.e. allowing
day driving for people whose seizures occur only at night or during sleep, cautious driving for those whose
seizures do not impair consciousness, or driving by those whose seizures have distinct warning signs that
allow them time to get o the road if one is oncoming), the loss of independence associated with the freedom
to drive is frustrating to many people with epilepsy.42 It has also been found that the risk of getting into
a seizure-related car accident decreases as the length of time since the last seizure increases.43 Eective
seizure control that can eliminate seizures entirely will therefore do much to give many seizure suerers their
freedom back.
Recreational Dangers
The nal danger associated with uncontrolled seizures stems from recreational activities, and tends to deprive
people of sports or games that they had previously enjoyed. Swimming, sailing, and other water-based
activities, for example, should be done only with precautions or under supervision, while sports like scuba
diving, skydiving, or motor racing must be avoided completely.44 Even sports in which a momentary loss of
attention would not itself lead to injury (soccer, tennis or basketball, for example) can lead to other problems
such as dehydration, overexertion and hypoglycemia, which put a person with epilepsy at an increased risk
of seizures.45 While the diagnosis of epilepsy itself can be very distressing, the physical, mental and
41Id.
42Id.
43Id.
44Id.
45Id.
13emotional eects of the condition and the currently available treatments can cause more problems for suerers
of the disorder on a day-to-day basis. Furthermore, restrictions on driving and recreational activities, as
well as a loss of educational and vocational opportunities, can lead to a very severe alteration in the quality
of life of people with uncontrolled seizures. Eective and side eect-free anti-epileptic drugs could remove
these barriers to living a normal life for people with the very common disorder of epilepsy. Discovery of such
drugs must therefore be a scientic priority.
The Basics of Epilepsy and its Treatment
The call for the development and improvement of anti-seizure medications does not mean that none currently
exist. In fact, there are over twenty medications on the market to treat epilepsy today, a tremendous
improvement from just twenty-ve years ago. Each has its strengths and weaknesses; no wonder drug has
been discovered yet. While one drug might oer impressive seizure control in adults, it might cause dangerous
rashes in children. The cognitive side eects of some drugs might make them unbearable to certain epilepsy
patients, while other patients might be more disturbed by gastrointestinal or behavioral side eects. More
importantly, each drug is particularly suited to treating one or more specic types of epileptic seizure; a
drug that provides wonderful control for the patient with absence seizures might do nothing at all for the
one with tonic-clonic seizures. 46 The choice of the appropriate medicine for the specic patient from among
the current arsenal is the most critical step toward deriving good seizure control with a minimum of side
eects.
Doctors today have other considerations as well in prescribing medications for patients with epilepsy. The
46See Scott, supra note 4, 88-89.
14current trend, due to reports of increased toxicity and long-term problems with use of multiple anti-epileptic
drugs, is toward monotherapy, the treatment of a patient with only one anti-epileptic drug. Finding that
drug and bringing it to a steady state in the patient's blood may be a time consuming trial-and-error process.
In 20 percent of patients, despite all the drugs available and the best eorts of their physicians, adequate
seizure control cannot be attained even if more than one drug is used.
The fact that some epilepsy patients cannot derive adequate seizure control from any of the over twenty
anti-epileptic drugs on the market and the fact that other patients can do so only at the cost of troubling
side eects make it clear that the call for new anti-seizure drugs is not due to a lack in quantity, but a lack in
the quality. People with epilepsy should not have to choose between dangerous seizures and \tolerable" but
highly unpleasant side eects. The great advances that have been made in treating epilepsy in the recent
past are evidence that improvements continue to be possible, especially with our ever-increasing scientic
knowledge, our understanding of the nature of epilepsy itself, and our awareness of how anti-epileptic drugs
interact with the body to prevent seizures.
What are Seizures, and How and Why do they Occur?
Before it is possible to determine an eective treatment for epilepsy, it is essential to understand the mech-
anisms by which seizures occur. Epilepsy, generally, is a disturbance in the electrical activity of the brain
in which the neurons become disturbed and begin to signal abnormally, creating \spikes" in the person's
brain waves.47 These spikes cause seizures, sudden interferences with behavior, perception, movement, con-
47Seizures and Epilepsy: Hope Through Research, supra note 2. See also Lechtenberg, supra note 24, at 4 {5.
15sciousness, or other brain functions.48 The disruption can occur due to an overly high level of excitatory
neurotransmitters, which increase neuronal activity, or an abnormally low level of inhibitory neurotransmit-
ters, which decrease neuronal activity.49 GABA (gamma-aminobutyric acid), an inhibitory neurotransmitter,
may be tied to epilepsy; some anti-epileptic drugs are designed to change the amount of GABA in the brain
or alter the brain's response to it.50 All anti-epileptic medications act to control the errant brain waves that
spike out of control when seizures take place.
The neuronal disturbance that leads to epileptic seizures can be caused by many things, including illness,
brain damage stemming from head injury or stroke, brain tumors, poisoning, alcoholism, infectious diseases
and abnormal brain development.51 Genetics also play an important role.52 Having a seizure does not mean
that you have epilepsy; in fact, many people have a single seizure at some point in their lives, never to have
one again. Though a single seizure might not indicate the disorder, somebody who suers from multiple
seizures is generally considered to have epilepsy.53
The search for the correct anti-seizure medication begins with a determination of the type of seizure from
which a person suers because dierent seizure types indicate dierent methods of treatment. There are
many types of seizures, each of which aects dierent parts of the brain in dierent manners.54 Simple
partial seizures, for example, occur in only one area of the brain. Their indicators are strange sensations or
sudden feelings of joy, sadness, or anger. The suerer does not lose consciousness in this type of seizure.55 A
more serious, though momentary, partial seizure is the complex partial seizure. Complex partial seizures
are the most common of all the seizures in adults.56 They too occur in just one area of the brain, but in
48Lechtenberg, supra note 24, at 4 { 5.
49Seizures and Epilepsy: Hope Through Research, supra note 2.
50Id.
51Id.
52Id.
53Comprehensive Epilepsy Center at Cornell Website at http://wo4.med.cornell.edu/cgi-bin/webobjects/pops-public.woa/wa/practice?name=comprehensive+Epilepsy+Center.
54For a description of the various types of seizures, see Lechtenberg, supra note 24, at 21 - 35.
55Seizures and Epilepsy: Hope Through Research, supra note 2.
56Schacter, supra note 23, at 58.
16this case the person might lose consciousness to some degree, often seeming to be in a dreamlike state and
displaying strange, repetitive behaviors called automatisms.57
Absence or petit mal seizures are yet another type of seizure. In this case the abnormal neuronal activity is
not conned to one area of the brain, making these generalized seizures. Absence seizures are characterized
by a loss of attention, in which the person stares o into space for ve to ten seconds and certain body parts
twitch or jerk.58 This type of seizure is very common among children with epilepsy.59 Other generalized
seizures include tonic, in which the person's muscles and body become sti and rigid, and clonic seizures,
which are accompanied by jerking movements. 60 When the characteristics of these two seizure types are
mixed, the person is said to have tonic-clonic (or grand mal) seizures.61 In tonic-clonic seizures the loss of
consciousness is sudden and the person's body becomes sti, then begins to jerk or twitch, possibly leading
to tongue biting and teeth grinding.62 These are the type of seizures most people associate with epilepsy.
Myoclonic seizures cause the person to jerk or twitch body parts due to sudden muscle contractions, while
and atonic seizures (drop attacks) cause a loss of muscle tone, leading to a sudden fall and possibly injury.63
The Goal of Anti-epileptic Drugs and the Mechanisms by which
they Work
The goal of an anti-seizure medication is to suppress the problematic brain waves by achieving what is known
as a \steady state" of medication in the blood. This steady state is the level at which seizures are controlled
57Seizures and Epilepsy: Hope Through Research, supra note 2.
58See Schacter, supra note 23, at 59. See also Seizures and Epilepsy: Hope Through Research, supra note 2.
59Schacter, supra note 23, at 59.
60Seizures and Epilepsy: Hope Through Research, supra note 2.
61Id.
62Schacter, supra note 23, at 59.
63Seizures and Epilepsy: Hope Through Research, supra note 2. See also id.
17or lessened, a level below which seizure control is ineective and above which the side eects of the drug
become intolerable.
Treatment begins with the oral administration of an anti-epileptic drug, whether in a pill, powder, or
syrup form. The drug is then absorbed through the intestines; from there it enters the blood stream,
where the plasma level rises.64 The blood then transports the drug to the person's brain, where it crosses
the blood/brain barrier. The brain concentration rises and the drug acts on neurotransmitters to prevent
epileptic seizures, possibly causing toxic eects as well.65 During the last stages of the treatment process,
metabolism and excretion are also occurring.66
The amount of the anti-epileptic drug in the blood (and through the blood, the brain) is not constant,
changing frequently due to its rate of absorption from the intestines, its distribution to dierent body parts,
its metabolism, and its excretion.67 Checking blood levels is an essential part of the treatment of those on
anti-epileptic medications to ensure that the amount of the drug in their bodies is maintained within the
specied range (the steady state).68
Achieving this steady state, and eliminating or lessening seizures, is preferably done with one drug (monother-
apy), though dicult to control seizures often require two or more drugs (polytherapy). Approximately 60
percent of epilepsy patients derive good seizure control from one medication, usually (in descending order)
phenytoin, carbamazepine, and valproate.69 Monotherapy allows for a larger therapeutic window, more ef-
fective seizure control, less potential for drug interactions, decreased risk of teratogenic eects (eects on a
developing fetus during pregnancy), better patient compliance, and increased cost-eectiveness.70 Polyther-
64Epilepsy Foundation of Victoria, Australia website at http://www.epinet.org.au/info/medication.html. See also Scott,
supra note 4, 142.
65Epilepsy Foundation of Victoria, Australia, supra note 64. See also Scott, supra note 4, 142.
66Scott, supra note 4, 142.
67Epilepsy Foundation of Victoria, Australia, supra note 64.
68See The EpiCentre, supra note 33.
69Lechtenberg, supra note 24, at 221.
70Schacter, supra note 23, at 69.
18apy is the less desired approach because many anti-seizure medications increase each other's side eects or
counteract each other's therapeutic eects, making a perfect combination dicult to come by.71 Each drug
may alter the absorption, metabolism, or excretion of any others taken, making a steady state dicult to
nd and maintain.72 The fact that each drug comes with its own set of side eects means that a person on
polytherapy is often exposed to a vast array of undesirable problems. Even if the medications are controlling
the patient's seizures, this multitude of side eects is often enough to cause noncompliance with the doctor's
prescription, leading to further seizures.
It is hoped that, with further research, drugs might become available that can reach a steady state in a
person's bloodstream while being prescribed at lower levels than necessitated by the current arsenal of med-
ications. This will increase the availability of monotherapy treatments for patients with previously hard to
control epilepsy, decrease undesirable side eects, and bring about a higher level of compliance with doctors'
orders.
How Does a Doctor Determine Which Medicine is Best?
The doctor's decision as to the medication of a specic patient is based primarily on which of the above-
described types of seizure a person experiences.73 The type of seizure suered by a particular patient is
determined by diagnostic testing, usually performed after the initial seizure and denitely after a second. In
ancient Greece, a potential method for determining whether or not a patient had epilepsy was to put the
person with seizures into a goat's skin, plunge him into the sea, and whether he oated or not determined if
71See The EpiCentre, supra note 33. See also Schacter, supra note 23, at 70.
72See Epilepsy Foundation of Victoria, Australia, supra note 64.
73Lechtenberg, supra note 24, at 8, 19.
19he had epilepsy (those so unfortunate as to sink were positively diagnosed with the disorder).74 The primary
diagnostic test today is the electroencephalogram (EEG), which can detect spiking in a person's brain waves
that may be characteristic of a specic type of epilepsy.75 A CT (computerized tomography) scan or an
MRI (magnetic resonance imaging) test may also be ordered to determine if there are any internal injuries or
lesions on the brain that may have caused the seizure.76 The results from these tests will help the doctor to
determine whether to medicate a person who has had only one seizure, which is usually done if the benets
of doing so (preventing a potential second seizure) outweigh the risks (undesirable side eects).77 Abnormal
spiking in the brain waves of the patient or a noticeable problem detected in the patient's CT scan usually
indicate immediate medication, as there is a good possibility that the person will eventually have another
seizure.
A second method of testing is through blood work, especially in childhood seizures. Blood tests can indicate
metabolic or genetic disorders that can cause seizures, or can notify the doctor of underlying causal conditions
such as infection, poisoning, anemia, or diabetes.78 These and spinal uid tests can assist the doctor in ruling
out other potential causes of nervous system disease.79
The most important part of the diagnostic process may be a taking of the personal and family medical
histories of the patient.80 The doctor must hear descriptions of the seizures from the patient, his or her
family, and any witnesses to the events. These provide important information as to the bodily reaction to the
neurological seizing, sometimes a denite indicator of the type of seizure involved.81 Past illnesses or injuries
that may have aected the person's brain or led to a lower seizure threshold must be disclosed, as should
74Temkin, supra note 5, at 26.
75Lechtenberg, supra note 24, at 192.
76See Lechtenberg, supra note 24, at 195, 196.
77Seizures and Epilepsy: Hope Through Research, supra note 2.
78Id. See also Fritz E. Dreifuss, Epilepsy: Standards of Medical Care in Epilepsy and Law 33, 38, supra note 21, at 38.
79Lechtenberg, supra note 24, at 197.
80Dreifuss, supra note 78, at 37. See also Schacter, supra note 23, at 58.
81A doctor would know, for example, that a person who fell to the oor and whose body was rigid was not having an absence
seizure, while a person who stared into the distance or performed automatisms was probably not suering from a tonic-clonic
t.
20any concurrent illnesses or changes in lifestyle, a family history of any neurological problems (due to the
possibility of genetic causes) and any problems during birth (such as oxygen deprivation).82 By indicating
the type of seizure involved, the descriptions contribute greatly to the choice of the proper medication.
In the end, the determination of which medicine is appropriate for a particular patient depends on a long
process of trial and error in which the physician and the person with epilepsy work together to determine
what level of seizure control is necessary (and attainable) and what types of side eects are unbearable
(and avoidable). In the best case scenario, the rst drug prescribed will work well for the patient, and after
reaching a steady state the patient can remain on monotherapy for long-term treatment. In the worst case
scenario, the doctor and patient try several drugs alone and then together, and still cannot achieve seizure
control. For this reason the arsenal of anti-epileptic drugs must keep growing.
The Current Arsenal of Anti-epileptic Drugs83
While the treatment of epilepsy has a long and varied history (discussed in the second section of this paper),
the rst eective anti-epileptic drugs were not introduced until 1857. It was then that Sir Charles Locock,
an English physician, noticed that bromides had a sedative eect and decided to try them on his seizure
patients.84 Because bromides were known to cause sexual impotence in men, Locock reasoned that they
82See Dreifuss, supra note 78, at 37.
83I did not cite each piece of information in the following paragraphs because it is, for the most part, widely
available. See generally Epilepsy Foundation of Victoria, Australia, supra note 64; The EpiCentre, supra note 33;
Johns Hopkins Epilepsy Center website at http://www.neuro.jhmi.edu/epilepsy/meds.html; Epilepsy Meds at adhdguide.net
website at www.adhdguide.net/pharmacy/epilepsy.
84Seizures and Epilepsy: Hope Through Research, supra note 2.
21might be useful as a treatment for seizures seemingly related to a woman's menstrual cycle.85 Though the
drugs had a fairly high level of toxicity, seizure relief was impressive.86
The modern conquest of epilepsy, which really began in the 1930's with the introduction of Dilantin, has
been a triumph of modern medicine, but still has far to go. The development of medications like Tegretol
and Depakote has provided seizure control to most patients with few unpleasant side eects.87 More recent
additions, like those developed and approved in the past ten years or the promising new drugs that are
currently being researched in clinical trials, have raised the standard even higher in terms of better seizure
control with fewer side eects; hopefully in ten years even they will obsolete. The research and development
of new anti-epileptic medications must continue until every case of epilepsy has a drug to match.
There are several considerations in choosing between the various drugs on the market today. Seizure type is
the rst; carbamazepine, for example, is a very good drug for tonic-clonic and partial seizures, but useless if
you have absence seizures. Vigabatrin, in fact, can make myoclonic epilepsy worse!88 Side eects are also a
consideration; phenytoin, for example, is not the proper drug for people whose job or educational pursuits
demand that they be especially awake or alert. There are considerations of the individual patient: youth
(lamotrigine should not be used), pregnancy (valproate may cause birth defects), or other illnesses (those
with liver disease should avoid felbatol). Use with MAO Inhibitors or tricyclic antidepressants increases the
toxicity of most of the anti-epileptic drugs.
The oldest of the rst-line drugs (principal drugs of rst choice) still prescribed today is phenytoin
(Dilantinr ). It was introduced in 1938, and remains the primary choice for monotherapy seizure control.
Phenytoin is used to control generalized tonic-clonic and complex partial seizures, but is ineective against
85Temkin, supra note 5, at 298.
86Id. at 299.
87The EpiCentre, supra note 33.
88Epilepsy Foundation of Victoria, Australia, supra note 64.
22absence seizures. It is also used to prevent and treat seizures related to neurosurgery.89 Though the drug
oers very good seizure control, it has a variety of short-term side eects including blurred or double vision,
drowsiness, unsteadiness, decreased coordination, mental confusion and slurred speech (symptoms similar
to, and potentially confused with, drunkenness90). It also can slow thought processes and reduce memory.91
More troubling, however, are the long-term side eects that accompany the chronic use of phenytoin, such
as the coarsening of facial features, overgrowth of gums, increase in body hair, and acne. Women with a
dark complexion should not use it.92 Though these are merely cosmetic (except for the gum overgrowth,
which can lead to serious problems), they represent a true hardship for those on the medication and are a
possible reason for noncompliance with a doctor's instructions. Phenytoin should not be used if the patient
is taking thyroid hormones, tricyclic antidepressants, and various other drugs, including the anti-epileptic
drug valproic acid. The ecacy of some birth control pills can be reduced if used with this drug.
Another commonly used rst-line drug is carbamazepine (Tegretolr ). Like phenytoin, it is very eective
against generalized tonic-clonic and simple and complex partial seizures, but not against absences. If the
initial dose is too high, the short-term side eects are similar to those for phenytoin, with nausea, dryness of
the mouth and giddiness a possibility as well. Most side eects disappear within the rst two weeks of use
as the patient's body adjusts to the drug. Reduction of the dose can lead to a reduction in the \drunk-like"
side eects, and a gradual introduction of the drug into the system may avoid them altogether.93 Serious
side eects, though rare, are jaundice and a lowering of the white cell count of the blood.94 A person should
89Johns Hopkins Epilepsy Center, supra note 83.
90See The EpiCentre , supra note 33.
91See id.
92Id.
93Id.
94Id.
23discuss any liver disease, blood cell or bone marrow problems, a drinking habit of over two drinks a day, or
depression with his doctor before taking the drug. Several drugs either aect or are aected by the presence
of carbamazepine in the patient's system, including birth control pills; as with all anti-epileptic medications,
it is essential for the patient to speak to his or her doctor or pharmacist about possible drug interactions
before taking the drug. Interactions with MAO inhibitors can be fatal.
Valproic Acid/Valproate (Depakoter ) is a third drug that is prescribed as monotherapy in newly di-
agnosed cases of epilepsy.95 It acts by increasing the brain's levels of the neurotransmitter GABA. It is
useful in combating generalized tonic-clonic seizures and partial seizures, as well as absences and myoclonic
seizures. Gastrointestinal side eects, such as diarrhea, abdominal pain, nausea, and vomiting are possible
accompaniments to this drug, as is weight gain. Drowsiness, tremor and hair loss may occur. Dizziness,
imbalance, and sedation are also possible if valproic acid is used with other drugs.96 Most serious but least
common are the liver damage, blood disorders (bleeding or bruising), or severe pancreatitis that can occur.97
may be caused by this medication. Common over-the-counter drugs, such as aspirin and antihistamines,
can increase the valproic acid levels in the blood, causing toxicity.98 Several other anti-epileptic drugs, such
as Felbamate, can aect or be aected by valproic acid, making it dicult to include this drug as part of
a polytherapy regimen. Carbonated beverages should be avoided while on this medication due to possible
irritation of the mouth and throat.
Ethosuximide (Zarontinr ) is the drug of choice for absence seizures, and is eective only in that type. Side
eects for the drug are behavioral disturbances, nausea and drowsiness, hiccups, headache, rash, decrease
in appetite, abdominal pain, and an unsteady walk. Sometimes it prevents absence seizures at the cost of
95For full information on Depakote, see patient prescription insert (Abbott Hospital).
96A chat room I visited at adhd.net, supra note83, more than conrmed people's unhappiness with the side eects of
Depakote. Among the complaints I witnessed were mood changes, nausea and heartburn, sleepiness, and confusion. They are
all dissatised, as was I, with the results of Depakote.
97See patient prescription insert for Depakote, supra note 95.
98Id.
24allowing, or maybe even causing, more serious tonic-clonic seizures.99
Some of the drugs used as adjunctive, or add-on, therapy include clonazepam (Klonopinr ), clobazam
(Frisumr ), clorazepate (Tranxener ), and diazepam (Valiumr ). Their eectiveness is wide-ranging:
clonazepam works against drop attacks, myoclonic, partial seizures and absences; clobazam against drop at-
tacks, generalized tonic-clonic, and partial seizures; and clorazepate works, along with Tegretol or Dilantin,
against complex partial seizures. Diazepam is recommended only for intermittent or emergency use for
managing status epilepticus. A problem with clonazepam, clobazam, and diazepam is that tolerance often
develops, requiring a higher dosage to get the same therapeutic eects. They usually are used on fairly weak
cases of epilepsy. Side eects for these drugs include drowsiness, sedation, poor coordination, depression,
weight gain, nausea, unsteadiness and slowing of mental performance. These sedative and dependency-
producing side eects limit their usefulness.
Primidone (Mysoliner  - introduced in 1954), along with Phenobarbital, the rst synthetic drug used to
treat epilepsy (introduced in 1912), was used mostly in the 1950's and 1960's.100 The original idea behind the
use of Phenobarbital stemmed from the realization that bromides worked to control epileptic seizures partly
due to their sedative nature.101 Phenobarbital, another sedative, was found to have the same anti-epileptic
eects, and when it was introduced it was the rst drug to provide a signicant degree of seizure control
to many people.102 It could not treat all seizure types, however, and had high levels of side eects, such
as inducing dependency, so the newer drugs gradually replaced it.103 Phenobarbital can treat generalized
seizures and some simple partial seizures. In high doses the side eects include lethargy, irritability, slurred
speech, and imbalance. Several drugs, including anti-epileptics and oral birth control pills, either aect or
are aected by Phenobarbital. Primidone works to control complex partial seizures. Once inside the body, it
99Scott, supra note 4, 99.
100Id. at 58.
101See id. at 59
102See Lechtenberg, supra note 24, at 224. See also Scott, supra note 4, at 59.
103Lechtenberg, supra note 24, at 224.
25is metabolized as Phenobarbital and thus the side eects are similar to phenobarbital's, including drowsiness
and hyperirritability, dizziness, double vision, sexual impotence and skin rash. Primidone also interacts with
several other anti-epileptic medications.
Vigabatrin (Sabrilr )is used to control partial or focal epilepsies and infantile spasms. It suppresses epileptic
seizures by enhancing the activity of the neurotransmitter GABA.104 Side eects for the drug are drowsiness,
diculty concentrating, mood changes, and possibly double vision, weight gain, and nausea. Fortunately the
side eects tend to be short-lived. Care must be exercised in prescribing vigabatrin to those with preexisting
psychiatric problems (one of the reasons it is essential to give the doctor a full health history when deciding
upon medications) because it is apt to cause psychotic episodes.
There are several drugs, released within the past decade, that show great promise in their ability to control
seizures with fewer side eects than their predecessors. They include felbamate, gabapentin, and lamotrigine.
Felbamate (Felbatolr  - approved by the FDA in 1993) is a drug used as monotherapy and add-on therapy
to treat secondarily generalized complex partial and tonic-clonic seizures in adults ages fourteen and over, as
well as Lennox-Gastaut syndrome in children two to fourteen years old.105 It is absorbed primarily though
the gastrointestinal tract and works by allowing GABA functioning and blocking voltage-dependent sodium
channels.106 It has the very serious potential side eects of reducing the body's ability to make blood cells
(aplastic anemia) as well as causing liver failure.107 A doctor must balance the risks and benets of using the
drug, and only do so if the epilepsy is so severe that the risk of aplastic anemia is worth taking felbamate in
104See The EpiCentre, supra note 33.
105Schacter, supra note 23, at 62
106Id.
107Id. at 41.
26order to treat it.108 Other problems with felbamate are its interactions with many other anti-epileptic drugs,
such as Dilantin, Tegretol, or Depakote. When combined with those drugs, side eects include headache,
nausea, vomiting, sleepiness, dizziness, and insomnia. Because of the interactions, it is essential that a
person on polytherapy using felbamate with other anti-epilepsy medications get frequent blood tests to
ensure maintenance of a steady state with each of the drugs.
Gabapentin (Neurontin r  - approved by the FDA in 1993) is recommended for use in treating dicult-
to-control complex partial seizures with or without secondary generalization in adults and partial seizures
in children between three and twelve years of age.109 The drug is structurally related to GABA, but it
is not known how it functions to control seizures.110 The side eects that were reported in trials include
sedation, dizziness, fatigue, unsteadiness, nausea and terror. In children ages three to twelve, other eects
were viral infection, somnolence, and hostility.111 According to the information booklet produced by its
manufacturer, Pzer Inc., Neurontin is the most frequently prescribed adjunctive anti-epileptic drug (beating
out lamotrigine, topiramate, levetiracetam, tiagabine, and zonisamide, in that order).112 Gabapentin does
not metabolize and is not bound to plasma proteins, making it useful as add-on therapy because interactions
with other anti-epileptic drugs do not seem to be signicant.113 It does not counteract the eects of oral
contraceptives and the fact that its titration can be rapid without toxic side eects should lead to increased
compliance with a doctor's prescription.114
108Id. at 62. Because of these risks, the drug is usually only used in cases of Lennox-Gastaut syndrome, where the severity of
the seizures and the need for control justies the risk.
109For complete information, see Neurontin booklet (Pzer Inc. 2001).
110See The EpiCentre, supra note 33. See also Neurontin booklet, supra note 109, at 26.
111See Neurontin booklet, supra note 109, at 7.
112Id. at 6, citing December 2000 Scott-Levin audit of uses by diagnosis.
113Schacter, supra note 23, at 63.
114See Neurontin booklet, supra note 109, at 7 - 9.
27Lamotrigine (Lamictalr  - approved by the FDA in 1994) is most eective in treating adults with partial
seizures and refractory generalized epileptic seizures115. It may also work for treating the seizures associated
with Lennox-Gastaut syndrome.116 Lamotrigine works in just the opposite manner of vigabatrin, reducing
the activity of the excitatory neurotransmitter glutamine by preventing its release from nerve endings.117
It is quickly and totally absorbed following oral administration.118 Slow and careful titration (increase in
dosage) is necessary when starting the drug to avoid a serious and potentially fatal rash or other allergic
reaction, which is most likely to appear in the early weeks of treatment. The possibility of a rash beyond that
time exists if a person exceeds the dosage prescribed by his or her doctor.119 The risk of rash is signicantly
greater in children than in adults.120 Valproic acid and lamotrigine counteract each other, with valproic acid
levels decreasing with the increase of lamotrigine. Taking valproic acid along with lamotrigine also increases
the risk of a dangerous rash.121 A further dermatological problem is rash caused by excessive exposure to
sunlight, so it is recommended that a person using the drug wear sunscreen or protective clothing when
outdoors.122 Side eects besides rash include nausea, dizziness, sleepiness, lack of coordination, nausea, and
blurred or, double vision.123 When taken with other drugs, drowsiness and sleepiness may occur. Lamot-
rigine also causes problems with folic acid synthesis, so women using the medication who plan to become
pregnant should take a folate supplement.
There are several other very recent additions to the anti-epileptic drug arsenal. Topiramate (Topamaxr  -
Approved by the FDA in 1996) acts by evening out the brain's electrical activity while blocking substances
115For more information about lamotrigine, see Lamictal Patient Prescription Insert (Glaxo Pharmaceutical).
116Schacter, supra note 23, at 64.
117See The EpiCentre, supra note 33.
118Schacter, supra note 23, at 64.
119See Lamictal Patient Prescription Insert, supra note 115.
120See Internet Drug Index website at www.rxlist.com.
121See Lamictal Patient Prescription Insert, supra note 115.
122Id.
123An additional side eect, known from personal experience and conversations in chat rooms at adhd.net, is a loss of short-term
memory, including words and names.
28that increase that activity, and in doing so signicantly reduces refractory partial and other seizures.124
Topamax was approved as adjunctive therapy for adults with partial onset seizures in December 1996.125
In September 2001 the FDA also approved the drug as add-on therapy for dealing with seizures in adults
with partial onset seizures and children with Lennox-Gastaut syndrome.126 When tested with other anti-
convulsants, patients reported poor coordination, slowed functioning, mood disorders, and slurred speech.
Topamax has interactions with several anti-epileptic drugs, making polytherapy dicult. It is important to
have high uid intake while taking the drug due to the slightly increased risk of kidney stones. It is also
important to note that topiramate does reduce the eectiveness of some birth control pills.
Tiagabine hydrochloride (Gabitrilr  - Approved by the FDA in 1997) controls partial seizures. It seems
to function on the brain to prevent seizures by inhibiting the neuronal reuptake of GABA, prolonging the
amount of time it is available at receptor sites. 127 Possible side eects are lightheadedness, lack of energy,
nausea, nervousness, tremor, abdominal pain, or diculty concentrating. The drug does interact with other
anti-epileptic medications, and polytherapy should be planned accordingly.
The newest drugs with high potential are levetiracetam (Keppra r  - Approved by the FDA in 1999),
zonisamide (Zonegranr  - Approved by the FDA in 2000), and oxcarbazepine (Trileptal { Approved by
the FDA in 2000), which is similar to carbamazepine but with fewer side eects.128
Levetiracetam oers control of refractory partial-onset seizures and perhaps generalized seizures as well.129
After oral administration the drug, like lamotrigine, is rapidly and almost totally absorbed into the sys-
124See The EpiCentre, supra note 33.
125Topamax Antiepileptic Drug Cleared by FDA (December 27, 1996) at Doctor's Guide website, http://www.docguide.com.
126Foundation Welcomes FDA Approval of Drug for Severe Epilepsy Syndrome (September 4, 2001) at
http://www.efa.org/epusa/media. See also FDA Approves Topamax (Topiramate) as Adjunctive Therapy for Lennox-Gastaut Syndrome
(September 4, 2001) and FDA Approves Topamax for Pediatric Epilepsy at Doctor's Guide website, http://www.docguide.com.
127See The EpiCentre, supra note 33. See also Schacter, supra note 23, at 65.
128Seizures and Epilepsy: Hope through Research, supra note 2.
129Schacter, supra note 23, at 66.
29tem.130 Side eects associated with levetiracetam include fatigue, dizziness, and infection.131 There is very
little potential for adverse interaction between this and other anti-epileptic drugs, and it does not aect the
ecacy of oral birth control pills.132
Zonegran was approved by the FDA in March of 2000 as add-on therapy for partial onset seizures, but it
may also be eective in treating generalized seizures, infantile spasms, the mixed seizure types associated
with Lennox-Gastaut syndrome, and myoclonic seizures.133 It lessens seizure activity is by blocking presy-
naptic voltage-sensitive sodium and calcium channels in neurons.134 The drug's safety and ecacy was
established in three multicenter placebo-controlled double-blind trials treating those with refractory partial
onset seizures.135 Reported side eects include drowsiness, lack of coordination, appetite loss or anorexia,
and impaired thinking and confusion.136 Two positive aspects of the drug that might improve patient com-
pliance with a doctor's prescription are its faster results (potentially reaches a steady state within two weeks)
and the need to take fewer pills (no dierence found between those who took one dose daily and those who
took two).137
The FDA also recently approved oxcarbazepine (Trileptalr ) in January 2000.138 139 The drug functions
by blocking voltage-sensitive sodium channels, stabilizing hyper-excited neural membranes, and inhibiting
repetitive neuronal ring.140 It can be used as monotherapy in adults with partial seizures or as adjunctive
130Id. at 66.
131Id. at 66-67.
132Id. at 66. See also Keppra (levetiracetam) Safe, Eective in Elderly with Epilepsy, Doctor's Guide at www.docguide.net.
133FDA Clearance of Zonegran Helps Meet Critical Need for New Therapies (March 28, 2000) at
http://www.efa.org/epusa/media. See also Schacter, supra note 23, at 68.
134FDA Clearance of Zonegran Helps Meet Critical Need for New Therapies, supra note 133.
135Internet Drug Index, supra note 120.
136FDA Clearance of Zonegran Helps Meet Critical Need for New Therapies, supra note 133.
137Internet Drug Index, supra note 120.
138For complete information on Trileptal, see Trileptal Informational Pamphlet (Novartis Pharmaceuticals 2000) and included
patient insert (Rev. January 2000).
139Epilepsy Foundation Says New Medication Brings Hope for Thousands Who Struggle with Seizures, Side Eects (January
17, 2000) at Epilepsy Foundation website at http://www.efa.org/epusa/media.
140See Tripetal patient insert, supra note 138.
30therapy in adults and children.141 Trials have shown its long-term safety and ecacy in treating children
with partial seizures, signicantly reducing seizure frequency with only mild and short-lived side eects.142
According to the informational booklet published by the drug's producer, Novartis Pharmaceuticals, the
reported side eects in clinical trials of the drug included dizziness, sleepiness, vision and gastrointestinal
problems, and a lack of coordination, but were often no dierent in the drug-treated population and the
placebo-treated population.143 Safety has been demonstrated in twenty-nine clinical studies with over three
thousand subjects and by use of the drug in other countries for more than ten years.144 It may soon be
approved for monotherapy use in children as well as adults.145 The drug should be used with care when
dealing with a patient who has a history of hypersensitivity to carbamazepine because they are chemically
and structurally similar.146 The drug may also reduce the eectiveness of oral contraceptives.147
Why Hasn't an Eective, Side Eect-free Anti-epileptic Drug Been Developed?
The reason for the current lack of side eect free anti-epilepsy medications that provide adequate seizure
control for every person with epilepsy may have less to do with the limits on modern science or the inca-
pacity of researchers to discover such a cure than with the diculties inherent in receiving approval for a
new anti-epileptic drug, rst as an add-on therapy, and later for use as a monotherapy. Despite the fact
that international pharmaceutical companies are striving to nd safer, more eective treatments for epilepsy
141Epilepsy Foundation Says New Medication Brings Hope for Thousands Who Struggle with Seizures, Side Eects, supra
note 139. See also Trileptal Informational Pamphlet, supra note 138.
142Sustained Benets Seen with Tripetal (Oxcarbazepine) as Adjunctive Therapy in Pediatric Partial-onset Seizures (Decem-
ber 5, 2001), Doctor's Guide website at http://www.docguide.com.
143Trileptal Informational Pamphlet, supra note 138.
144Id.
145Sustained Benets Seen with Tripetal (Oxcarbazepine) as Adjunctive Therapy in Pediatric Partial-onset Seizures, supra
note 142.
146See id. See also Trileptal Informational Pamphlet, supra note 138; Schacter, supra note 23, at 67.
147Schacter, supra note 23, at 67.
31that will succeed in the current twenty-ve drug marketplace, new drugs are not cascading onto the market
because of the high cost of research, development and marketing (more than $150 million per drug).148
Though it would seem that, because doctors ardently support monotherapy as opposed to polytherapy, new
drugs approved for monotherapy would be pouring onto pharmacy shelves, that is not the case. The clinical,
procedural, and ethical limitations placed on researchers in getting such drugs approved slow the process
signicantly. Most drugs that are currently on the market are approved only for add-on therapy use.149 An
individual doctor who realizes that one of these medications would be eective and safe for his patient as a
primary, monotherapy drug may not prescribe the drug as such, but must do so \o-label", which leads to
problems with legal liability and insurance reimbursement.150
Before a drug can be approved at all (either for mono or polytherapy), there must be extensive and expensive
clinical testing. The tests must rst be done on animals to prove the drug's safety, ecacy, and its eects
on reproduction.151 Only after those factors have been positively established can the investigational drug
trials, with humans aicted with the disorder as the subjects, be commenced.152 At that stage the drug is
tested for safety and long-term eectiveness under testing conditions carefully monitored by the FDA.153
For an anti-epileptic drug to obtain approval from the FDA, researchers must prove a dierence in treat-
ment eect between the drug being tested and a placebo (an inert substance or sugar pill not intended to
provide any positive eect).154 For this reason, new drugs are usually approved only as add-on medications
so that patients can stay on their normal treatment regimen while completing the trial, instead of forcing
half of the study population to rely only on a placebo to ensure seizure control.155 Receiving approval of
148The EpiCentre, supra note 33
149Workshop on Antiepileptic Drug (AED) Monotherapy Indication (March 8-9 2001), sponsored by the National Institute of
Neurological Disorders and Stroke, National Institute of Health (NINDS/NIH), the American Epilepsy Society (AES), Citizens
United for Research in Epilepsy (CURE), and the Epilepsy Foundation (EF), available at www.nih.com.
150Id.
151See Comprehensive Epilepsy Center at Cornell, supra note 53, section on Investigational Drug Trials.
152Id.
153Id.
154Workshop on Antiepileptic Drug (AED) Monotherapy Indication, supra note 149.
155Id.
32a new epilepsy drug (or one currently approved only for add-on therapy) for use as monotherapy is more
problematic because trials that use a placebo as the only treatment for a person with epilepsy increase the
danger of seizures and may cause the trial participant harm, which is ethically unjust.156When a placebo
controlled monotherapy trial does occur, it is essential that the researchers are prepared for any emergency
that might result from a lack of treatment in the placebo population, and have appropriate safety mecha-
nisms in place.157 If it is hoped that the drug will control a certain type of seizure, such as the relatively
benign brief absence, myoclonic, or simple partial seizures, and only patients with those type of seizures are
involved in the study, the risk is not as great that harm will be done to the patient if seizures occur during
placebo use as it is with populations with more severe seizures.158 One option is to use a \pseudo-placebo"
(an active medication, but given in doses signicantly lower than those needed for patient treatment) to get
the blind trial eect without entirely depriving epilepsy patients of active drugs.159 This method was used
in the trials to gain monotherapy approval for the drug felbamate; Valproate was used as a pseudo-placebo
to show ecacy.160
The approval process as it currently stands makes it very dicult for new anti-epileptic drugs to reach the
market, both initially as add-on drugs and later as drugs for monotherapy. The trials are costly and time
consuming, replete with ethical issues of patient treatment and its deprivation in the name of science, and
have a high likelihood of subject withdrawal from the trial.161 The FDA has recently indicated some de-
gree of willingness to consider using a testing mechanism favored in Europe, whereby new medications for
156See Joyce A. Cramer, Ethical Issues in the Planning and Conduct of Clinical Drug Trials 13, 16 in Epilepsy and Law, supra
note 21. See also Workshop on Antiepileptic Drug (AED) Monotherapy Indication, supra note 149.
157Cramer, supra note 136, at 15. Such trials often occur in hospital settings, for example.
See also Workshop on Antiepileptic Drug (AED) Monotherapy Indication, supra note 149.
158Cramer, supra note 136, at 16.
159Id. See also Workshop on Antiepileptic Drug (AED) Monotherapy Indication, supra note 149.
160Cramer, supra note 136, at 16.
161Workshop on Antiepileptic Drug (AED) Monotherapy Indication, supra note 149.
33monotherapy are tested through \control equivalence trials"162This type of trial involves comparing a poten-
tial new anti-epileptic drug with a well-established drug that is generally considered to be eective.163This
testing format would promote the development of new anti-epileptic drugs for monotherapy by eliminating
the safety and ethical concerns about placebo-controlled monotherapy drug trials.164
Special Considerations in Treating Women with Epilepsy
Women with epilepsy face a number of problems specic to their sex and the situations connected with it.
Hormones, for example, are known to play an important role in the triggering of seizures in many women.
This can explain why many women's initial seizures occur during the teenage years, during pregnancy or
upon entering old age (and menopause), all times when hormone levels are surging, dipping, and changing
day-to-day. The same hormonal uctuations can lead to breakthrough seizures in teenage or pregnant women
whose epilepsy had previously been controlled, requiring a reevaluation of their treatment strategy.165 It
has also been noticed that, for many women, the menstrual cycle and the hormonal changes that accompany
it are responsible for triggering seizures. Seizures that occur around the time of menstruation are called
catamenial seizures.166 This can be diagnosed by obtaining blood tests to detect hormone levels as soon
after a seizure as possible, or by a woman simply keeping a journal of where she was in her monthly cycle when
a seizure occurred. The knowledge of whether her seizures are hormonally triggered can be very useful to a
woman in her daily lifestyle choices; she might refrain from driving or other potentially dangerous activities,
162Id.
163Id.
164Id.
165Dreifuss, supra note 78, at 40.
166Lechtenberg, , supra note 24, at 11.
34for example, during the time in the month when her seizures usually occur, and rest easy throughout the
rest of her cycle. Medication considerations might also be aected if a woman suers these menstrual-based
seizures; changing the dosage of her regular medication or adding an adjunctive therapy during specic
points in her cycle may control the seizures.167
A major concern for women with epilepsy is pregnancy. Both the ability to get pregnant, the desire not to
get pregnant and the ability to carry a healthy baby to full term may be aected by the disorder and the
medications used to control it. The ability to get pregnant is, again, tied to hormones. The disturbance
in hormonal activity that can trigger many women's seizures can also result in a failure to ovulate and a
condition known as polycystic ovarian syndrome (PCOS), making pregnancy very dicult. Furthermore,
some seizure medications and some types of epilepsy can reduce a person's interest in sexual activity, which
is an obvious hindrance to becoming pregnant. 168 These concerns, along with an actual choice among
women worried about passing on the disorder or the inability to nd a suitable marriage partner, contribute
to the fact that women with epilepsy have fewer pregnancies than women in the general population.169 The
desire not to get pregnant is also aected, as many anti-epileptic drugs counteract the eects of birth control
pills, rendering them useless against preventing conception.
For a woman who does desire to be a mother, the problems do not end with conception. She must rst nd
a neurologist and an OB/GYN who are willing to work together and with her to ensure that the pregnancy
goes as smoothly as possible. Many doctors still have the outdated belief that an epileptic woman should
not get pregnant at all, as it is seen as dangerous for both the baby and the mother. However, most doctors
167Id.
168See Seizures and Epilepsy: Hope Through Research, supra note 2, section on Pregnancy and Motherhood.
169Lechtenberg, supra note 24, at 86.
35today see no obstacles to having a healthy baby as long as the pregnancy is carefully planned and carefully
monitored.
The key considerations in dealing with an epileptic woman's pregnancy are whether she will take medica-
tion(s), which medication(s) she will take, and at what dosage. Most doctors are in agreement that the most
important thing in producing a healthy baby is preventing seizures altogether, and if medication is needed
to produce that result, than medication should be taken.170 A fetus is at great risk of harm due to a lack
of oxygen if severe seizures during pregnancy are not prevented.171 Epilepsy is associated with an increased
number of miscarriages in early pregnancy, a greater chance of premature labor, and the possibility of injury
due to a seizure.172 Severe, or even minor, seizures during pregnancy can harm the developing baby and
trauma associated with them can cause late-term miscarriage.173 However, not all epileptic women will need
to take medications during pregnancy, and it may be decided that the risk of having a seizure during the
pregnancy is outweighed by the risks of drug related fetal side eects, especially if the woman has only mild
seizures or has not had any at all in a long time.174
The goal in medicating a pregnant woman is to have the mother on monotherapy (one medication) throughout
the pregnancy, as more than one medication can have increased side eects (and possibly damaging eects
on the fetus) and make dosage more dicult to monitor. The rate of birth defects among the unaected
population is 2 to 3 percent.175 That risk is two to three times greater among women taking one anti-
epileptic drug during pregnancy, and even more complications occur if the woman is on polytherapy instead
170National Study to Assess Impact of Anti-seizure Medications on Unborn Children (2001), Medical College of Georgia news
brief, available on their website at www.mcg.edu/news/2001newsrel/meador.htm.
171The EpiCentre, supra note 33, section called How Safe are Anti-epileptic Drugs in Pregnancy? See also Lechtenberg, supra
note 24, at.91.
172The EpiCentre, supra note 33, section called How Safe are Anti-epileptic Drugs in Pregnancy?
173Seizures and Epilepsy: Hope Through Research, supra note 2, section on Pregnancy and Motherhood. See also
National Study to Assess Impact of Anti-seizure Medications on Unborn Children, supra note 170.
174The EpiCentre, supra note 33, section called How Safe are Anti-epileptic Drugs in Pregnancy?
175National Study to Assess Impact of Anti-seizure Medications on Unborn Children, supra note 170.
36of monotherapy. 176 Whereas normally drugs may be taken twice daily, it is better to avoid blood levels
peaking too high by administering drugs (especially valproic acid) more frequently (3 or 4 times a day) in
smaller doses.177
Another goal is to have the mother on the lowest dosage possible that can still provide adequate control
of her seizures.178 Because the drugs pass through the placenta from mother to baby, it is obvious that,
the lower the dose, the less risk of a harmful eect on the fetus.179 Because a woman's hormone levels are
changing almost constantly during pregnancy and drugs are metabolized dierently, however, maintaining
a steady state and keeping her at the lowest possible dose require frequent blood testing, as does the fact
that a woman's increased blood volume may dilute her medication. 180 An increase in total daily dosage is
often required as the mother's size increases, but the dose must be lowered again immediately after delivery.
181 Again, a neurologist and OB/GYN willing to work together are essential in ensuring the mother's and
fetus's safety. 182 Women with epilepsy may notice a change in seizure frequency during their pregnancies;
24 to 40 percent experience an increase, while others notice a decrease.183
Each year over 24,000 babies are born to women with epilepsy, but there is still no anti-epileptic drug known
to be entirely safe during pregnancy.184 The decision about which drug to take is very important. For a
176Lechtenberg, supra note 24, at 95. See also The EpiCentre, supra note 33, section called
How Safe are Anti-epileptic Drugs in Pregnancy?
177Lechtenberg, supra note 24, at 95.
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Pregnancy and Motherhood.
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37woman with complex partial seizures, carbamazepine is a good drug choice during pregnancy.185 Between
carbamazepine, Depakote, and phenytoin, however, it is not known which carries the greatest risk of creating
fetal abnormalities.186 There is some evidence that where there is a family history of neural tube defects,
phenytoin is the safest of the three.187 Reports that valproic acid causes disturbances in neural tube closure,
however, have been somewhat contradicted by the many women who have had healthy babies after taking the
drug during pregnancy.188 Regardless of whether a woman takes phenytoin, carbamazepine, or valproic acid
to control seizures during pregnancy, it is essential that she also take folate supplements to reduce the risk of
neural tube defects, the negative eects of which range from trivial abnormalities of the vertebrae to major
abnormalities like maldevelopment of the spinal cord and spina bida.189 190 Carbamazepine and valproic
acid are possibly linked to spina bida, while face or skeletal problems may appear in babies whose mothers
took phenytoin during the rst trimester of pregnancy.191 Valproic acid, Trimethadione, and phenytoin are
known to also increase the risk of a child having birth defects such as cleft palate, heart problems, or nger
and toe defects.192 A woman's doctor may advise her to switch to other medications during pregnancy.193
It is essential to note that the listing of the possible adverse reactions during pregnancy for the older drugs
does not indicate that the newer drugs do not present similar problems; it is yet unknown what eects on
the fetus many of them will have.194 All anti-epileptic drugs have some risks accompanying their use during
pregnancy; the doctor and patient should carefully balance the risk to the fetus should a seizure occur with
the risks of birth defects associated with a particular drug, and only use the medication if the rst risk
185Lechtenberg, , supra note 24, at 94.
186The EpiCentre, supra note 33, section called How Safe are Anti-epileptic Drugs in Pregnancy?
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38outweighs the second.
Careful planning is one of the most important aspects of a healthy pregnancy for an epileptic woman. It is
essential that a woman provide her doctor with enough notice of her desire to get pregnant that he will be
able to switch her to a medication more compatible with pregnancy if necessary or make the decision to take
her o of medication entirely.195 Both decisions should be considered as far in advance of the pregnancy as
possible. Switching medications often requires time to slowly remove a patient from one and reach a steady
state on another, usually with some trial and error. In terms of taking the woman o medication completely,
it is important to know whether she will have rebound seizures or be able to handle the frequency of the
minor seizures she had been controlling up to that point. Clearly it is better to gure these things out prior
to the pregnancy. It is also important for the mother begin prenatal vitamin supplements, especially folic
acid, well before pregnancy. This can counteract or reduce the possibility of birth defects due to anti-epileptic
drugs.196 Careful planning makes this possible.
The birth itself is not usually a problem for epileptic women, although there is a slightly increased risk
for hemorrhage, eclampsia, premature labor and cesarean section.197 Doctors can administer anti-epileptic
drugs intravenously if labor triggers a seizure.198 Babies sometimes have symptoms of withdrawal from the
mother's seizure medications after they are born, but these problems wear o soon and do not usually cause
long term side eects.199
The dangers associated with women and epilepsy do not stop at the birth of a healthy child. Having a
baby, even a healthy one, entails a lot of stress and frequent sleep deprivation, both triggers for epileptic
seizures. Many new mothers whose seizures are not completely controlled worry about having a seizure while
195Seizures and Epilepsy: Hope Through Research, supra note 2, section on Pregnancy and Motherhood.
196Id. See also National Study to Assess Impact of Anti-seizure Medications on Unborn Children, supra note 170.
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39holding their child. Furthermore, breastfeeding may be an issue, depending on the drug that the mother is
taking. Many of the currently available drugs can be excreted through breast milk, but the minor amounts
are less than the baby was exposed to in the womb.200 Though the baby may become overly drowsy or
feed poorly, which should be closely monitored, in most cases doctors believe the benets of breastfeeding
outweigh the risks. 201Again, a doctor must closely monitor the levels of the drug in the mother's body to
determine whether such excretions would be harmful to the baby and perhaps require bottle-feeding or a
change in the mother's medication. Some drugs are not recommended at all for breast-feeding mothers (i.e.
lamotrigine).202
Despite the fears and precautions involved, the vast majority of epileptic women who become pregnant have
uneventful pregnancies and produce happy, healthy babies. In total, women with epilepsy have only a 4-6%
chance of having a baby with birth defects.203 Furthermore, the risk that the child of a parent with epilepsy
will develop epilepsy his or herself is only about 5%, unless the parent has a clearly hereditary form of
the disorder.204 With careful planning and monitoring, there is no reason for the birth of a healthy infant
not to occur. Working toward this goal are a number of national registries that have been set up, through
which women who are taking anti-epilepsy medications while pregnant can provide information on the health
of their children in return for being given information on proper planning for an epileptic pregnancy and
information on the anti-epileptic medications available for mothers. One such registry is at the Massachusetts
General Hospital.205 Together, women, their doctors, and researchers in these registries can help to nd safe
200Id. See also Lechtenberg, , supra not 24, 98.
201Seizures and Epilepsy: Hope Through Research, supra note 2, section on Pregnancy and Motherhood.
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40and eective drugs to treat the woman-specic aspects of epilepsy.
Special Considerations in Treating Children or the Elderly
As many as one out of fty children is believed to have epilepsy.206 The causes of epilepsy in children may
be related to injury as fetuses or during birth. The developing brain is very sensitive and problems such as
maternal infections, poor nutrition, or oxygen deciencies can aect the fetus' brain and make him or her
susceptible to seizures.207 Genetics often play a role as well.
An epilepsy syndrome that is frequent in childhood is absence epilepsy, in which the child has repeated
absence seizures that cause a momentary lapse of consciousness. Teachers and parents often think the child
is just daydreaming or not paying attention.208 Though this may cause problems in school, the seizures
usually stop at puberty and cause no lasting damage.209 Ethosuximide, a drug made specically for absence
seizures, oers a red syrup form for children due to the prevalence of this type of seizure in that age group.210
Temporal lobe epilepsy with partial seizures also frequently begins in childhood, but is not harmless like the
aforementioned absence seizures. Over time it can cause the hippocampus to shrink, having lasting eects on
learning and memory, so it is essential to have early and eective treatment for this type of epilepsy.211 Fol-
lowing a double-blind, randomized, placebo-controlled trial in which researchers found a 33 percent seizure
206Schacter, supra note 24, 57.
207Seizures and Epilepsy: Hope Through Research, supra note 2.
208\Understanding Epilepsy" by Epstein
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41reduction rate in pediatric patients, the FDA approved Topamax as adjunctive therapy to threat childhood
partial seizures.212 Reported side eects were drowsiness, loss of appetite and corresponding weight loss,
and diculty concentrating.213 The FDA also recently approved a new drug called oxcarbazepine (Tripetal)
to treat such partial seizures in children, currently only as adjunctive therapy, but possibly as monotherapy
in the future.214 It has been shown to be safe, eective, and tolerable as add-on therapy for children with
hard-to-control seizures.215 Monotherapy would be an even better approval because children's monotherapy
options are very limited (only ve other anti-epileptic drugs are approved for monotherapy use in children)
and polytherapy creates problems with drug interactions and increased side eects.216
Lennox-Gastaut syndrome is an even more devastating type of childhood epilepsy. Children aicted with
it have a wide combination of seizure types, making treatment very dicult.217 They are subject to a high
risk of cognitive and behavioral disabilities.218 The disease usually is diagnosed between the ages of three
and ve years old, with more than 1,400 new cases diagnosed each year.219 Felbamate is one drug used in
its treatment, as is a newer option called topiramate, which was approved as add-on therapy for treatment
of the condition in September 2001.220 221 In clinical trials, the most common side eects seen in chil-
dren taking the drug along with their current anti-epileptic drug regimen were excessive drowsiness, loss of
appetite, fatigue, nervousness, diculty with concentration, weight loss, aggressive reaction, and memory
212FDA Approves Topamax (Topiramate) as Adjunctive Therapy for Lennox-Gastaut Syndrome (September 4, 2001), Doc-
tor's Guide website at http://www.docguide.com.
213Id.
214Sustained Bene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42diculties.222 Rasmussen's encephalitis is also a very severe disorder in which half of the child's brain shows
continual inammation, sometimes requiring the radical surgical treatment of a hemispherectomy.223
Other types of childhood epilepsy begin in infancy, such as infantile spasms. This syndrome does not respond
to conventional anti-epileptic drugs.224
Children with epilepsy are subject to many hardships beyond those that adults with epilepsy suer. Di-
culty in concentrating, lack of memory, or hyperactivity are side eects of many anti-epileptic medications,
making schoolwork dicult. Children are generally more subject to cruel treatment by their peers than
adults are, and it is apt to aect them more signicantly. The special restrictions, constant administration
of anti-epileptic drugs, and learning or behavior disorders associated with childhood epilepsy may make par-
ents overly-protective of their child, with this sheltering leading to further problems in social interactions.225
Overall, children with epilepsy are subject to more behavioral and learning disorders than children in the
general population.226 They also sometimes exhibit violent, destructive behavior not common in other chil-
dren.227
When choosing a medication for a child or elderly person with epilepsy, the doctor must consider the mode
of administration. Among both children and the elderly, many people with epilepsy cannot (or will not)
swallow a pill or capsule, especially since many epilepsy medications (such as Depakote) are rather large. It
is essential, then, to choose an anti-epileptic drug that comes in syrup or powder form (powders can be either
water soluble or sprinkled on food). The older rst-line drugs, such as phenytoin, carbamazepine, sodium
valproate, and ethosuximide come in syrup form; some newer medications, such as vigabatrin, come in an
oral powder.228 The makers of Topamax, recently approved by the FDA as a treatment for Lennox-Gastaut
222FDA Approves Topamax (Topiramate) as Adjunctive Therapy for Lennox-Gastaut Syndrome, supra note 212.
223Seizures and Epilepsy: Hope Through Research, supra note 2.
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43syndrome (commonly associated with childhood) took this into account in making their medication in cap-
sules that can be opened and sprinkled onto food for ease in swallowing.229 Neurontin (gabapentin), which
is approved for adjunctive treatment of partial seizures in children, oers a child-friendly oral solution with
a \cool strawberry-anise avor".230 This makes administration much easier for a parent or caretaker, less
of a problem for the person with epilepsy, and increases the likelihood of maintaining the prescribed drug
regimen.
Certain drugs pose distinctive problems for children. Valproic acid, for example, has been known to cause
acute liver disease, and even failure, in children who have severe seizures along with mental retardation, are
on polytherapy, and/or have metabolic problems or brain disorders.231 These risks are increased if the child
is under two years of age.232 The benzodiazapines group of drugs (including clorazepate and clonazepam),
though they cause sedation in adults, can cause hyperactivity and drooling in children.233 Clonazepam can
also cause withdrawn behavior, mood swings, and auditory hallucinations.234 Phenobarbital (and also myso-
line, which is metabolized as Phenobarbital), can cause a severe hyperirritability syndrome in children.235
Ethosuximide, which is used to treat the generalized absence seizures that aect many children, can also
cause irritability, interference with sleep patterns, and night terrors in young children.236 Lamotrigine's risk
of a serious, life-threatening rash is much higher among children than adults, and therefore the drug is not
available for children under sixteen years old except for treatment of Lennox-Gastaut syndrome.237
The elderly are another population prone to epilepsy and special consideration must be given to their specic
229See FDA Approves Topamax (Topiramate) as Adjunctive Therapy for Lennox-Gastaut Syndrome, supra note 212
230See Neurontin Pamphlet, supra note 109, at 21.
231See The EpiCentre, supra note 33. See also Depakote Patient Prescription Insert, supra note 95.
232See Depakote Patient Prescription Insert, supra note 95.
233Johns Hopkins Epilepsy Center, supra note 83.
234Lechtenberg, supra note 24, at 131.
235Johns Hopkins Epilepsy Center, supra note 83. See also Lechtenberg, supra note 24, at 131; Scott, supra note 4, at 67.
236Lechtenberg, supra note 24, at 131.
237Internet Drug Index, supra note 120.
44anti-epileptic drug needs. There are currently 555,000 elderly people with seizure disorders, so doctors must
know of the specic medicating needs of that population.238 When evaluating an elderly person with epilepsy
and determining which medication might be most eective in his or her treatment, it is again important to
consider that the causes of their epilepsy may dier signicantly from those of a younger patient. Stroke and
heart attacks, which deprive the brain of oxygen, are causes of epilepsy more common among the elderly.239
About 32 percent of recently developed epilepsy in the elderly population seems to be related to another
condition that reduces the availability of oxygen to the brain cells called cerebrovascular disease.240 Finally,
Alzheimer's disease, which occurs among the elderly, can also cause epileptic seizures to begin.241
A consideration when dealing with the elderly, regardless of the cause of their seizures or the medication
they use to control them, is the fact that people become more sensitive to medications as they get older,
requiring frequent blood tests to be certain that a steady state is maintained.242
Selecting the correct anti-epileptic drug for an elderly patient is essential. Adequate seizure control is very
important in this group of individuals because the average elderly patient tends to be more physically fragile
than a younger patient. Severe grand mal seizures, for example, can harm the elderly by causing spine
fractures due to the force of spinal muscle contractions.243 A fall might cause an older person to break a
bone or fracture a hip. Seizure control is necessary to prevent the physical injuries extending beyond the
seizure itself.
238New Epilepsy Treatment Guidelines Reect Signicant Changes in Drug Choices (11/26/01), Doctor's Guide at
www.docguide.com
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240Id.
241Id
242Id.
243Lechtenberg, supra note 24, at 23.
45Some medications have more harmful eects in the elderly than in the general population. Not only do the
elderly tend to have a higher percentage of other treated or untreated conditions which use of the wrong anti-
epileptic drug could exacerbate, but they also seem to suer increased side eects from normally prescribed
drugs.244 Phenobarbital, for example, is known to cause depression in the rest of the population, but its
eects are even greater among the elderly.245 Neurontin should also be used with great care among the
elderly due to a higher frequency of decreased hepatic, renal, or cardiac function, the possibility of other
concurrent illnesses, and interactions with the medications used to treat these conditions.246 Fortunately
drugs like Keppra, which was recently approved by the FDA as add-on therapy for epilepsy treatment in the
elderly, has a very low risk of the drug/drug interactions that often make prescribing anti-epileptic drugs to
the elderly dicult.247Also, the side eects of the drug, such as sleepiness, confusion, hostility and insomnia,
were not much greater in the elderly than in other age groups taking this medication.248
Special Considerations in Treating Patients with Other Ailments
This section is obviously closely related to the prior section in dealing with limitations placed on doctors in
prescribing medications to those with other physical problems, except in this section the problems apply to
all age groups. People with illnesses other than epilepsy must be careful and work closely with their doctors
when selecting an anti-epileptic drug. Not only do many anti-epileptic drugs counteract the medicinal eects
244Keppra (levetiracetam) Safe, Eective in Elderly with Epilepsy, supra note 132.
245Scott, supra note 4.
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46of drugs used to treat other ailments, but several of the epilepsy medications themselves are dangerous to
someone with an underlying medical condition.
Because most epilepsy medications are processed through the liver and the blood, those with problems
related to either must be wary in choosing a drug. Carbamazepine can cause a lowering of the white blood
cell count and jaundice due to liver impairment.249 Sodium valproate is known to cause acute liver failure
in some cases, and should be avoided entirely by those who have a history of liver disease.250 Lamotrigine
should also be used with care in any patient with renal, hepatic, or cardiac problems because any functional
impairment could change the way the body metabolizes or eliminates the drug, causing decreased eectiveness
or toxicity.251
Future Developments in the Search for a Miracle Drug
The NINDS sponsors research on the development, causation, and treatment of seizures and epilepsy's eects
on brain activity and development.252 It also plays a signicant role in the search for and development of
new anti-epileptic drugs through its Epilepsy Therapeutics Research Program, which has screened 22,000
compounds in its 25-year history and has contributed to the development of ve drugs now approved for use
in the United States.253 The search continues for new drugs that can be taken less frequently and control
seizures with fewer unpleasant side eects.254
249The EpiCentre, supra note 33.
250Id.
251See Internet Drug Index, supra note 120.
252Seizures and Epilepsy: Hope Through Research, supra note 2.
253Id.
254Lechtenberg, supra note 24, 216.
47In creating new anti-epileptic medications, researchers continue to examine the roles neurotransmitters, such
as GABA and glutamate, as well as injuries to cell membranes play in causing seizures.255 NMDA receptors
and potassium channels are also potential neural targets for anti-epileptic drugs; research is currently being
done in this innovative area.256 Researchers are studying the contribution of glia and other non-neuronal cells
in the brain to seizures, hoping that this will lead to new treatments.257 Gene research is also a major factor
in determining why some people are more susceptible to seizures and perhaps why some are more resistant to
anti-epileptic medications.258 Identifying genes that inuence epilepsy could help in the development of new
anti-epileptic drugs, and so-called \gene chips" that allow a doctor to determine a patient's genetic makeup
might make the choice of medications simpler and faster.259 Each of these lines of research is leading to new
information and new understandings about the very makeup of the human brain, what makes it susceptible
to epilepsy, and what can alleviate that susceptibility.
One innovative treatment option currently being pursued is the use of stem cell transplants to bring GABA
producing neurons into the brains of those with seizures. Another is a potential device that could detect
changes in the brain that precipitate a seizure, thus allowing the patient to move to safe place or, even better,
release a drug or electric impulse into the brain to avoid the seizure altogether.260 A recently approved
device called the vagus nerve stimulator (approved by the FDA in 1997) is a further glimpse into the future
of epileptic treatment.261 For those whose seizures are not controlled by anti-epileptic medications, using
this device as add-on therapy may provide a good deal of relief. The device is implanted in the patient's
left upper chest with a connection to the left vagus nerve in the person's neck. The generator can then
255Seizures and Epilepsy: Hope Through Research, supra note 2.
256Natalie Frazin, supra note 1, referring to comments by Dr. Raymond Dingledine of Emory University.
257Seizures and Epilepsy: Hope Through Research, supra note 2.
258Id.
259Id. See also Natalie Frazin, supra note 1.
260Seizures and Epilepsy: Hope Through Research, supra note 2. See also Natalie Frazin, supra note 1.
261For a description of the device and its functions, see Schacter, supra note 23, at 72. See also Audrey T. Hingley,
Epilepsy: Taming the Seizures, Dispelling the Myths, the FDA website at www.fda.gov/fdac/features/1999/199 epil.html.
48deliver intermittent stimulation to the brain to prevent, interrupt, or reduce the severity of a seizure. The
side eects of the implantation are only those usually associated with a chest surgery, such as incisional
pain, coughing and nausea. Besides that, however, the device reduces seizures without the side eects that
usually accompany anti-epileptic drugs. The treatments that researchers can imagine and modern science
can produce have almost no limit. One doctor at the White House conference on epilepsy envisioned a device
which, when implanted in the brain, could attract axons and actually alter the brain's circuiting.262 This
device, though it may not be a reality yet, demonstrates the extents to which scientists will go in trying to
eliminate seizures.
Although some of the aforementioned treatments are not new anti-epileptic medications, they would certainly
be a welcome addition to the arsenal with which researchers, doctors, and patients continue to battle the
crippling eects of uncontrolled epileptic seizures and the troublesome eects of the medications that attempt
to control them. The search for the miracle cure for epilepsy continues and if the pace of discovery in the
past ten years is any indicator, it will not be long before an eective, side eect-free treatment for epilepsy
will be available to oer true seizure relief for the millions who suer from this very common disorder.
262See Natalie Frazin, supra note 1, referring to comments by Dr. Daniel Lowenstein from the University of California, San
Francisco.
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